Inhibition of in vitro tumor cell proliferation by cytokines induced by combinations of TLR or TLR and TCR agonists

International Immunopharmacology

Volumn 7, Issue 11, 2007, Pages 1471-1482

  Ghosh, Tarun K ^a   Mickelson, Dan J ^a   Lipson, Kenneth E ^a   Alkan, Sefik S ^a  

^a 3M COMPANY   (United States)

Author keywords

Interferons; Synergism; T cell receptor; Toll like receptors; Tumor growth inhibition

Indexed keywords

ALPHA INTERFERON; GAMMA INTERFERON; IMIDAZOQUINOLINE DERIVATIVE; INTERLEUKIN 6; INTERLEUKIN 8; T LYMPHOCYTE RECEPTOR; TOLL LIKE RECEPTOR 4 AGONIST; TOLL LIKE RECEPTOR 7 AGONIST; TOLL LIKE RECEPTOR 8 AGONIST; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; CANCER CHEMOTHERAPY; CELL KILLING; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; TUMOR CELL; TUMOR CELL LINE; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOKINES; HUMANS; INTERFERON TYPE II; LEUKOCYTES, MONONUCLEAR; MICE; RECEPTORS, ANTIGEN, T-CELL; TOLL-LIKE RECEPTORS;

EID: 34548126484     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2007.06.002     Document Type: Article

References (51)

1. Plautz G.E., Miller D.W., Barnett G.H., Stevens G.H., Maffett S., Kim J., et al. T cell adoptive immunotherapy of newly diagnosed gliomas. Clin Cancer Res 6 6 (2000) 2209-2218
2. Virasch N., and Kruse C.A. Strategies using the immune system for therapy of brain tumors. Hematol Oncol Clin North Am 15 6 (2001) 1053-1071
3. Liau L.M., Black K.L., Martin N.A., Sykes S.N., Bronstein J.M., Jouben-Steele L., et al. Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case Report. Neurosurg Focus 9 6 (2000) e8
4. Liau L.M., Black K.L., Prins R.M., Sykes S.N., DiPatre P.L., Cloughesy T.F., et al. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J Neurosurg 90 6 (1999) 1115-1124
5. Prins R.M., and Liau L.M. Immunology and immunotherapy in neurosurgical disease. Neurosurgery 53 1 (2003) 144-152 [discussion 52-3]
6. Walker P.R., Calzascia T., de Tribolet N., and Dietrich P.Y. T-cell immune responses in the brain and their relevance for cerebral malignancies. Brain Res Brain Res Rev 42 2 (2003) 97-122
7. Smyth P., Sheils O., Finn S., Martin C., O'Leary J., and Sweeney E.C. Real-time quantitative analysis of E-cadherin expression in ret/PTC-1-activated thyroid neoplasms. Int J Surg Pathol 9 4 (2001) 265-272
8. Yang L., and Carbone D.P. Tumor-host immune interactions and dendritic cell dysfunction. Adv Cancer Res 92 (2004) 13-27
9. Finn O.J. Cancer vaccines: between the idea and the reality. Nat Rev Immunol 3 8 (2003) 630-641
10. Acres B., Limacher J.M., and Bonnefoy J. Discovery and development of therapeutic cancer vaccines. Curr Opin Drug Discov Devel 10 2 (2007) 185-192
11. Flynn J.L., Chan J., Triebold K.J., Dalton D.K., Stewart T.A., and Bloom B.R. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 178 6 (1993) 2249-2254
12. Murray H.W. Current and future clinical applications of interferon-gamma in host antimicrobial defense. Intensive Care Med 22 Suppl 4 (1996) S456-S461
13. Bahnson R.R., and Ratliff T.L. In vitro and in vivo anti-tumor activity of recombinant mouse tumor necrosis factor (TNF) in a mouse bladder tumor (MBT-2). J Urol 144 1 (1990) 172-175
14. Kirkwood J.M., and Ernstoff M.S. Role of interferons in the therapy of melanoma. J Invest Dermatol 95 6 Suppl (1990) 180S-184S
15. Decker T., Stockinger S., Karaghiosoff M., Muller M., and Kovarik P. IFNs and STATs in innate immunity to microorganisms. J Clin Invest 109 10 (2002) 1271-1277
16. Katze M.G., He Y., and Gale Jr. M. Viruses and interferon: a fight for supremacy. Nat Rev Immunol 2 9 (2002) 675-687
17. Koga S., Nishikido M., Matsuya F., Kanetake H., and Saito Y. Subcutaneous administration of interferon alpha and gamma in patients with metastatic renal cell carcinoma. Anticancer Res 19 6C (1999) 5547-5550
18. Akira S., and Takeda K. Toll-like receptor signalling. Nat Rev Immunol 4 7 (2004) 499-511
19. Tomai M.A., Miller R.L., Lipson K.E., Vasilakos J.V., and Woulfe S.L. Immune response Modifiers: Imiquimod and future drugs for modulating the immune response. Drug Discovery Today: Therapeutic Strategies (2006) 343-352
20. Kawai T., and Akira S. Innate immune recognition of viral infection. Nat Immunol 7 2 (2006) 131-137
21. Liu Y.J. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 23 (2005) 275-306
22. Krug A., Luker G.D., Barchet W., Leib D.A., Akira S., and Colonna M. Herpes simplex virus type 1 activates murine natural interferon-producing cells through Toll-like receptor 9. Blood 103 4 (2004) 1433-1437
23. Kasai H., He L.M., Kawamura M., Yang P.T., Deng X.W., Munkanta M., et al. IL-12 Production Induced by Agaricus blazei Fraction H (ABH) Involves Toll-like Receptor (TLR). Evid Based Complement Alternat Med 1 3 (2004) 259-267
24. Germann T., Gately M.K., Schoenhaut D.S., Lohoff M., Mattner F., Fischer S., et al. Interleukin-12/T cell stimulating factor, a cytokine with multiple effects on T helper type 1 (Th1) but not on Th2 cells. Eur J Immunol 23 8 (1993) 1762-1770
25. Tilg H., Vogel W., Tratkiewicz J., Aulitzky W.E., Herold M., Gruber M., et al. Pilot study of natural human interleukin-2 in patients with chronic hepatitis B. Immunomodulatory and antiviral effects. J Hepatol 19 2 (1993) 259-267
26. Tomova R., Pomakov J., Jacobs J.J., Adjarov D., Popova S., Altankova I., et al. Changes in cytokine profile during local IL-2 therapy in cancer patients. Anticancer Res 26 3A (2006) 2037-2047
27. Napolitani G., Rinaldi A., Bertoni F., Sallusto F., and Lanzavecchia A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol 6 8 (2005) 769-776
28. Gelman A.E., Zhang J., Choi Y., and Turka L.A. Toll-like receptor ligands directly promote activated CD4+ T cell survival. J Immunol 172 10 (2004) 6065-6073
29. Sobek V., Birkner N., Falk I., Wurch A., Kirschning C.J., Wagner H., et al. Direct Toll-like receptor 2 mediated co-stimulation of T cells in the mouse system as a basis for chronic inflammatory joint disease. Arthritis Res Ther 6 5 (2004) R433-R446
30. Sato S., Nomura F., Kawai T., Takeuchi O., Muhlradt P.F., Takeda K., et al. Synergy and cross-tolerance between Toll-like receptor (TLR) 2- and TLR4-mediated signaling pathways. J Immunol 165 12 (2000) 7096-7101
31. Caron G., Duluc D., Fremaux I., Jeannin P., David C., Gascan H., et al. Direct stimulation of human T cells via TLR5 and TLR7/8: flagellin and R-848 up-regulate proliferation and IFN-gamma production by memory CD4+ T cells. J Immunol 175 3 (2005) 1551-1557
32. Ghosh T.K., Mickelson D.J., Fink J., Solberg J.C., Inglefield J.R., Hook D., et al. Toll-like receptor (TLR) 2-9 agonists-induced cytokines and chemokines: I. Comparison with T cell receptor-induced responses. Cell Immunol 243 1 (2006) 48-57
33. Ghosh T.K., Mickelson D.J., Solberg J.C., Inglefield J.R., Lipson K.E., and Alkan S.S. TLR-TLR cross talk in human PBMC resulting in synergistic and antagonistic regulation of Type 1 and 2 interferons, IL-12 and TNF-α. Int Immunopharmacol 7 8 (Aug 2007) 1111-1121
34. Ghosh TK, Mickelson DJ, Solberg JC, Inglefield JR, Lipson KE, and Alkan SS. Co-Activation of Toll-like receptor (TLR) and T-cell receptor (TCR) results in synergistic up-regulation of IFN-γ and IL-12p70 responses (submitted for publication).
35. Gorski K.S., Waller E.L., Bjornton-Severson J., Hanten J.A., Riter C.L., Kieper W.C., et al. Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists. Int Immunol 18 7 (2006) 1115-1126
36. Ogata M., Matsumoto T., Koga K., Takenaka I., Kamochi M., Sata T., et al. An antagonist of platelet-activating factor suppresses endotoxin-induced tumor necrosis factor and mortality in mice pretreated with carrageenan. Infect Immun 61 2 (1993) 699-704
37. Shen D.W., Cardarelli C., Hwang J., Cornwell M., Richert N., Ishii S., et al. Multiple drug-resistant human KB carcinoma cells independently selected for high-level resistance to colchicine, adriamycin, or vinblastine show changes in expression of specific proteins. J Biol Chem 261 17 (1986) 7762-7770
38. Ahmed S.A., Gogal Jr. R.M., and Walsh J.E. A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to [3H]thymidine incorporation assay. J Immunol Methods 170 2 (1994) 211-224
39. LeBouder E., Rey-Nores J.E., Raby A.C., Affolter M., Vidal K., Thornton C.A., et al. Modulation of neonatal microbial recognition: TLR-mediated innate immune responses are specifically and differentially modulated by human milk. J Immunol 176 6 (2006) 3742-3752
40. Trinchieri G., and Scott P. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions. Res Immunol 146 7-8 (1995) 423-431
41. Horikoshi T., Fukuzawa K., Hanada N., Ezoe K., Eguchi H., Hamaoka S., et al. In vitro comparative study of the antitumor effects of human interferon-alpha, beta and gamma on the growth and invasive potential of human melanoma cells. J Dermatol 22 9 (1995) 631-636
42. Gutterman J.U. Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci U S A 91 4 (1994) 1198-1205
43. Pfeffer L.M., Dinarello C.A., Herberman R.B., Williams B.R., Borden E.C., Bordens R., et al. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res 58 12 (1998) 2489-2499
44. Krown S.E. Interferon treatment of renal cell carcinoma. Current status and future prospects. Cancer 59 3 Suppl (1987) 647-651
45. Almeida A., Correia-da-Silva G., Cepa M., Bell S.C., and Teixeira N.A. Synergistic induction of apoptosis in primary rat decidual cells by INF-gamma and TNF. Mol Reprod Dev 74 3 (2007) 371-377
46. Lee N.C., Tsung K., and Norton J.A. Production of interferon-gamma by tumor-sensitized T cells is essential for interleukin-12-induced complete tumor eradication. Surgery 132 2 (2002) 365-368
47. Leon C., Nandan D., Lopez M., Moeenrezakhanlou A., and Reiner N.E. Annexin V associates with the IFN-gamma receptor and regulates IFN-gamma signaling. J Immunol 176 10 (2006) 5934-5942
48. Egwuagu C.E., Li W., Yu C.R., Che Mei Lin M., Chan C.C., Nakamura T., et al. Interferon-gamma induces regression of epithelial cell carcinoma: critical roles of IRF-1 and ICSBP transcription factors. Oncogene 25 26 (2006) 3670-3679
49. Presti R.M., Popkin D.L., Connick M., Paetzold S., and Virgin H.W.T. Novel cell type-specific antiviral mechanism of interferon gamma action in macrophages. J Exp Med 193 4 (2001) 483-496
50. Brandacher G., Winkler C., Schroecksnadel K., Margreiter R., and Fuchs D. Antitumoral activity of interferon-gamma involved in impaired immune function in cancer patients. Curr Drug Metab 7 6 (2006) 599-612
51. Thomas-Tikhonenko A., and Hunter C.A. Infection and cancer: the common vein. Cytokine Growth Factor Rev 14 1 (2003) 67-77